Q2
AIRS — Q2 2026 Financial Report Analysis
AirSculpt's same-center cases rose 1% but revenue fell 2.5% to $42.9M as price per case slipped and marketing cost per patient jumped 19%; adjusted EBITDA guidance cut to $12-14M and lenders set an Oct 31 refinancing deadline.